Evaluate Sunosi® PK in Breast Milk and Plasma of Healthy Postpartum Women Following Single Dose Oral Administration

NCT05008341 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Narcolepsy
Obstructive Sleep Apnea
Excessive Daytime Somnolence
Excessive Sleepiness
Postpartum

Interventions

DRUG: Solriamfetol 150 mg Oral Tablet

Sponsor

Axsome Therapeutics, Inc.